Literature DB >> 24275117

MICs of 32 antimicrobial agents for Rhodococcus equi isolates of animal origin.

Anne Riesenberg1, Andrea T Feßler, Erdal Erol, Ellen Prenger-Berninghoff, Ivonne Stamm, Reinhard Böse, Anton Heusinger, Dieter Klarmann, Christiane Werckenthin, Stefan Schwarz.   

Abstract

OBJECTIVES: The aim of this study was to determine the MICs of 32 antimicrobial agents for 200 isolates of Rhodococcus equi of animal origin by applying a recently described broth microdilution protocol, and to investigate isolates with distinctly elevated rifampicin MICs for the genetic basis of rifampicin resistance.
METHODS: The study included 200 R. equi isolates, including 160 isolates from horses and 40 isolates from other animal sources, from the USA and Europe. MIC testing of 32 antimicrobial agents or combinations thereof followed a recently published protocol. A novel PCR protocol for the joint amplification of the three rpoB regions in which rifampicin resistance-mediating mutations have been reported was applied to isolates with elevated rifampicin MICs. The amplicons were sequenced and screened for mutations.
RESULTS: Susceptibility testing revealed a rather uniform distribution of MICs for most of the antimicrobial agents tested. The lowest MICs were seen for clarithromycin, rifampicin and imipenem. Six isolates (3%) exhibited distinctly higher MICs of rifampicin than the remaining 194 isolates. In five of these six isolates, single bp exchanges, which resulted in the amino acid exchanges Gln513Leu, Asp516Val, His526Asp or Ser531Leu, were detected in the rifampicin resistance-determining region 1 of the rpoB gene, with Gln513Leu representing a novel substitution for R. equi.
CONCLUSIONS: This study shows the MIC distribution of 32 antimicrobial agents for a large collection of R. equi isolates of animal origin from two continents. Isolates that exhibited distinctly elevated MICs of rifampicin were only rarely detected.

Entities:  

Keywords:  broth microdilution; horses; rifampicin; rpoB

Mesh:

Substances:

Year:  2013        PMID: 24275117     DOI: 10.1093/jac/dkt460

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi.

Authors:  Londa J Berghaus; Steeve Giguère; Kristen Guldbech; Eleanor Warner; Ukachi Ugorji; Roy D Berghaus
Journal:  J Clin Microbiol       Date:  2014-11-05       Impact factor: 5.948

2.  Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice.

Authors:  Alexandra J Burton; Steeve Giguère; Londa J Berghaus; Mary K Hondalus
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

3.  Effect of Macrolide and Rifampin Resistance on Fitness of Rhodococcus equi during Intramacrophage Replication and In Vivo.

Authors:  Jennifer M Willingham-Lane; Londa J Berghaus; Roy D Berghaus; Kelsey A Hart; Steeve Giguère
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

4.  Effect of Macrolide and Rifampin Resistance on the Fitness of Rhodococcus equi.

Authors:  Jennifer M Willingham-Lane; Londa J Berghaus; Roy D Berghaus; Kelsey A Hart; Steeve Giguère
Journal:  Appl Environ Microbiol       Date:  2019-03-22       Impact factor: 4.792

5.  Emergence of Resistance to Macrolides and Rifampin in Clinical Isolates of Rhodococcus equi from Foals in Central Kentucky, 1995 to 2017.

Authors:  Laura Huber; Steeve Giguère; Nathan M Slovis; Craig N Carter; Bonnie S Barr; Noah D Cohen; Justine Elam; Erdal Erol; Stephan J Locke; Erica D Phillips; Jacqueline L Smith
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 6.  Epidemiology and Molecular Basis of Multidrug Resistance in Rhodococcus equi.

Authors:  Sonsiray Álvarez-Narváez; Laura Huber; Steeve Giguère; Kelsey A Hart; Roy D Berghaus; Susan Sanchez; Noah D Cohen
Journal:  Microbiol Mol Biol Rev       Date:  2021-04-14       Impact factor: 11.056

7.  Efficacy of Tulathromycin for the Treatment of Foals with Mild to Moderate Bronchopneumonia.

Authors:  D Rutenberg; M Venner; S Giguère
Journal:  J Vet Intern Med       Date:  2017-04-19       Impact factor: 3.333

8.  Clonal Confinement of a Highly Mobile Resistance Element Driven by Combination Therapy in Rhodococcus equi.

Authors:  Sonsiray Álvarez-Narváez; Steeve Giguère; Elisa Anastasi; Jack Hearn; Mariela Scortti; José A Vázquez-Boland
Journal:  mBio       Date:  2019-10-15       Impact factor: 7.867

9.  Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi.

Authors:  Erdal Erol; Mariela Scortti; Jordan Fortner; Mukesh Patel; José A Vázquez-Boland
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

Review 10.  Membrane transport systems and the biodegradation potential and pathogenicity of genus Rhodococcus.

Authors:  Carla C C R de Carvalho; Sofia S Costa; Pedro Fernandes; Isabel Couto; Miguel Viveiros
Journal:  Front Physiol       Date:  2014-04-04       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.